clairop

How to Afford Ulcerative Colitis Medication

1 in 6 US adults with IBD skip medication because of cost. How to lower what you pay for mesalamine and biologics, plus appeals and UK/Canada notes.

Clairop Team24 min read

Photo: Beth Macdonald / Unsplash

The short answer

To afford ulcerative colitis medication in the US, work through the price levers in order: generic versus brand, plan formulary and exceptions, a 90-day supply, manufacturer programs (commercial insurance only), nonprofit grants, and Medicare Extra Help or hospital aid. Never skip, stretch or share doses to save money; tell your IBD team about cost first, because they can often help.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Ulcerative colitis medication costs depend on your drug and your coverage, and most people lower the bill by pulling several levers: a generic where one exists, a 90-day supply, plan exceptions and appeals, manufacturer programs (commercial insurance only), nonprofit grants, and Medicare Extra Help or hospital aid. In the US, 15.5% of adults with IBD report skipping medication because of cost (Liu 2026). Tell your team before you cut anything.

This guide is written from a US point of view first, because that is where most of the cost problem lives, with short sections on the UK and Canada near the end. Insurance rules change every year and differ by plan, state and country, so treat this as a map of the options and a checklist of questions, not a quote. We deliberately do not print drug prices: they vary too much by plan and pharmacy to be useful, and they go out of date quickly. What we can do is show you where the price comes from and who can move it.

Why does ulcerative colitis medication cost so much?

Ulcerative colitis usually needs long-term treatment, so even modest per-prescription costs repeat for years. The American College of Gastroenterology guideline lists aminosalicylates, steroids, biologics and small molecules as the core drug families (Rubin 2025), and NIDDK notes that people typically need lifelong medicine unless they have surgery (NIDDK). Costs stack across drugs, visits, labs and infusions. Weighing whether a biologic is worth it at all? See are biologics worth it for ulcerative colitis?.

A narrative review of 18 US studies found patient-level direct costs for IBD ranged widely, from about 7,800 to 41,800 dollars a year, with pharmacy costs making up anywhere from 7% to 51% of that. Crohn's disease cost more than ulcerative colitis, and active, severe disease cost more than quiet disease (Kahn-Boesel 2023). The same review linked financial distress to delays in care and to cost-related medication nonadherence.

Two national analyzes show the pattern is not confined to people without insurance. In 2015 survey data, 23% of adults with IBD reported hardship from medical bills, 16% reported cost-related nonadherence, and the problem appeared even among people with private insurance and higher incomes, which the authors attributed to underinsurance (Nguyen 2021). More recent data put cost-related nonadherence at 15.5% for adults with IBD versus 8.2% for matched controls, with higher odds under age 65, with lower income and without insurance (Liu 2026).

What do people with ulcerative colitis say about paying for medication?

A common theme in r/UlcerativeColitis is that the answer depends almost entirely on where you live and what coverage you have. In threads such as where are you from and how is your medication paid for, people in the US describe a mix of employer insurance, deductibles that reset each January and manufacturer programs, while people in the UK, parts of Europe and Australia describe public systems with little or no charge.

Other threads, such as does anyone actually pay for medication and how do people afford being sick, show Canadians comparing provincial plans and drug-company compassionate programs, and US posters pointing newcomers to manufacturer savings programs. There is also a long-running thread on affording mesalamine.

Two caveats. First, forum answers are anecdotes from different countries, drugs and plan years; they tell you what to ask about, not what you will pay. Second, some posters mention offering or accepting leftover pills. That is not a safe route, and we explain why below.

How can I afford mesalamine?

Mesalamine is an aminosalicylate used to bring on and maintain remission in mild to moderate ulcerative colitis (NIDDK). To lower what you pay, ask your pharmacist which generic forms exist, ask about a 90-day fill, and compare plan and cash prices. Your prescriber chooses the form; do not switch products yourself.

DailyMed, the US National Library of Medicine's label database, lists generic mesalamine in several forms, including delayed-release tablets, extended-release and delayed-release capsules, suppositories and rectal suspension (DailyMed mesalamine labels). That does not mean every form you might be prescribed has a generic, or that your plan prefers it. The FDA states that approved generics are required to match the brand in dosage, safety, effectiveness, strength, stability and quality (FDA).

Here is a practical order of questions to take to your doctor's office and pharmacy.

  1. Is a generic available for the exact form I am prescribed? If the doctor wrote a brand name, ask whether "substitution permitted" is possible or whether there is a medical reason for the brand.
  2. Is it on my plan's formulary, and at which tier? A non-preferred tier can cost more than a preferred alternative.
  3. Can I fill 90 days at once, or use the plan's mail-order pharmacy? Some plans charge one copay for 90 days instead of three. This usually does not apply to injections and infusions (MyCrohnsAndColitisTeam).
  4. What is the cash or discount-card price compared with my plan price? See the next section before you decide.
  5. Has my deductible reset? Many people see a price spike in the first months of the year, then a drop after the deductible is met. Ask whether timing matters for your plan.

How much does mesalamine cost?

There is no honest single number. The price you pay depends on the form (tablet, capsule, suppository or enema), whether a generic exists for it, your plan's tier and deductible, the pharmacy and whether you use insurance or cash. Instead of a quote, get three numbers for the same prescription: your plan price, a published cash price and a discount-card price.

One reason people are surprised is that the label for a product tells you how it must be taken, and some forms are not interchangeable with each other. For example, the prescribing information for one delayed-release 1.2 g tablet says to swallow tablets whole and not to split or crush them, and to evaluate kidney function before starting and periodically on treatment (DailyMed Lialda label). A cheaper-looking route that involves splitting, a different strength or someone else's supply can undo the design of the product and skip the monitoring.

Form your doctor may prescribeWhere the cost usually comes fromQuestions to ask
Oral delayed-release tablet or capsuleBrand versus generic, tier, quantity per dayIs there a generic of this exact form? Can I get 90 days?
Suppository or enemaGeneric status and availability vary by product and pharmacyWhich pharmacies stock it? Is there a plan-preferred version?
Other older oral or rectal medicinesOften lower cost, but formulary rules still applyIs there a prior authorization or quantity limit?
Biologic infusionBilled through a clinic or hospital, often under the medical benefitIs the clinic in network? Is there a manufacturer program and an infusion-site cost?
Biologic injection or oral small moleculeSpecialty pharmacy, prior authorization, high list priceIs there a savings card or assistance program? Who files the prior authorization?

Can discount cards and cash-price pharmacies lower the price?

Sometimes. A discount card or an online pharmacy that publishes cash prices can beat a plan price for some generics. The catch is that cash or card purchases often do not count toward your deductible or out-of-pocket maximum, so compare your total yearly cost, not just one fill (MyCrohnsAndColitisTeam).

US posters in r/UlcerativeColitis often mention checking Cost Plus Drugs and GoodRx for generics, and some say formulary changes left them paying full price on a plan. We could not verify current prices for any named service, and prices change, so treat these as places to compare rather than recommendations. Practical rules that hold regardless of which service you use:

  • Use the same pharmacy and the same exact product when you compare, otherwise the numbers mean nothing.
  • Ask whether the cash price is for the form and quantity you actually take.
  • If you are likely to reach your deductible or out-of-pocket maximum this year anyway, using your plan may be cheaper overall, even if a card wins on one fill.
  • Be careful with cards and sites that ask for lots of personal information, and use only pharmacies licensed in your state.
  • Tell your pharmacist if you use a card, so they can still check for interactions across all your medicines.

How do copay cards and manufacturer programs work for biologics and newer drugs?

Biologics and newer oral drugs for ulcerative colitis are brand-name products, so manufacturers run their own support programs. Copay or savings cards are for commercially insured patients; patient assistance programs (free-drug programs) are a separate route with income rules. Federal anti-kickback law is why copay cards are kept away from Medicare and Medicaid patients (OIG).

The HHS Office of Inspector General explains that coupons and similar direct support to insured patients can be remuneration under the anti-kickback statute when a federal health program pays for the drug, and notes that coupons typically carry a statement that they may not be used with federal programs (OIG). In plain terms: if you have employer or marketplace coverage, a copay card may be available; if you have Medicare or Medicaid, ask about the manufacturer's patient assistance program or other routes instead.

People in r/UlcerativeColitis describe a range of outcomes: some pay almost nothing per infusion because of a manufacturer program layered on top of their insurance, while others still pay a lot until a deductible is met. Posts also mention programs for specific drugs and that some assistance programs help with part of the deductible. Check each company's current terms, because eligibility rules, annual limits and enrollment steps change.

Two things to watch with commercial coverage:

  • Accumulators and maximizers. Some plans and employers use copay accumulator or maximizer programs so that manufacturer support does not count toward your deductible or out-of-pocket maximum, which can leave you facing a large bill once the card is used up. A pharmacy-policy primer describes how these programs work and why they add complexity to specialty drugs (Choi 2024). Ask your plan directly whether manufacturer assistance counts toward your deductible.
  • Who enrols you. Many manufacturer programs have a nurse or case manager who helps with insurance checks and prior authorization. Ask your IBD clinic whether they have a contact for the specific drug.

The Crohn's & Colitis Foundation keeps a searchable list of financial assistance programs. At the time we checked it listed 71 resources, including copay card programs and pharmaceutical financial aid programs for named drugs (Crohn's & Colitis Foundation). Programs open, close and change, so call to confirm.

What if I have Medicare or Medicaid?

Medicare Part D has a yearly out-of-pocket limit: Medicare states spending on covered Part D drugs is capped at 2,100 dollars in 2026 and 2,400 dollars in 2027, after which covered drugs cost nothing for the rest of the year (Medicare.gov). Extra Help, state programs and a payment-spreading plan can lower or smooth costs further.

Medicare's own pages list the main routes (Medicare.gov):

  • Extra Help, a program for people with limited income and resources. You qualify automatically if you have Medicaid, a Medicare Savings Program or Supplemental Security Income, and others can apply (Medicare.gov).
  • State Pharmaceutical Assistance Programs, which some states run to help with premiums or cost sharing.
  • Manufacturer pharmaceutical assistance programs, which some companies offer to people with Part D; each has its own eligibility rules.
  • The Medicare Prescription Payment Plan, which spreads your out-of-pocket costs across the calendar year. It changes when you pay, not the total.

Part D covers prescriptions you fill at a pharmacy. Infusions given in a clinic are often billed through the medical benefit rather than the pharmacy benefit, so it is worth asking the infusion center how your own drug is billed and what your share will be. Medicaid benefits and cost sharing vary by state; your state Medicaid office or the clinic's social worker can tell you what applies to you.

What if I have no insurance or just lost it?

Ask about three things at once: the manufacturer's patient assistance program, a nonprofit grant and the hospital's financial assistance policy. None of these is guaranteed, and each has its own paperwork, so start early and ask your IBD clinic's social worker, nurse or pharmacist who handles the forms.

  • Manufacturer patient assistance. This is separate from the commercial copay card and usually has income limits. The Crohn's & Colitis Foundation's list includes pharmaceutical financial aid programs (Crohn's & Colitis Foundation).
  • Nonprofit funds. Independent charities such as the HealthWell Foundation help with prescription copayments, coinsurance, deductibles and premiums for people who already have health insurance (HealthWell Foundation). Disease funds can open and close as money runs out, so check current status.
  • Hospital financial assistance. Nonprofit hospital organizations must have a written financial assistance policy for emergency and other medically necessary care, and it must be widely publicized (IRS). If you get infusions, scopes or labs at such a hospital, ask the billing office for the policy.
  • Coverage options. Losing a job or income may open a chance to get coverage through a marketplace or Medicaid. Eligibility and enrollment windows depend on your state and situation, so ask the clinic's social worker or a licensed navigator.
  • Community tools. MyCrohnsAndColitisTeam points to the America's Medicines assistance tool and NeedyMeds as places to search for programs (MyCrohnsAndColitisTeam).

What can I do when insurance denies or delays my medication?

Find out what kind of "no" it is, then work the matching route: a prior authorization to be completed, a step-therapy rule to be answered, a formulary or tier exception to be requested, or a denial to be appealed. Your prescriber's office usually leads, and a letter explaining why this drug is needed matters most.

Prior authorization is a real clinical problem, not just paperwork. In a retrospective study of 190 children with IBD starting biologics at one hospital, prior authorization added about 10 days to the time from recommendation to first dose, complicated authorizations (needing appeal, step therapy or peer-to-peer review) added about 25 days, and prior authorization was associated with more IBD-related healthcare use and more steroid dependence at 90 days (Constant 2022). It was a single-center pediatric study, so it shows a pattern rather than a number for you. A gastroenterology paper on the process notes that step therapy and payers not recognizing updated IBD treatment pathways often drive denials, and offers tips for practices (Bhat 2019).

For Medicare Part D, CMS explains that an enrollee, prescriber or representative can request a tiering exception (a non-preferred drug at preferred-tier cost sharing) or a formulary exception (a drug not on the formulary, or a waiver of step therapy, prior authorization or quantity limits). Exceptions are granted when the plan finds the drug medically necessary, so the prescriber must submit a supporting statement (CMS).

For plans covered by the federal appeal rules on HealthCare.gov, the steps are:

  1. Denial notice. The insurer must notify you in writing within 15 days for a prior authorization, 30 days for services already received and 72 hours for urgent care (HealthCare.gov).
  2. Internal appeal. You have 180 days from the denial notice. A letter from the doctor helps, and your state's Consumer Assistance Program can file for you (HealthCare.gov).
  3. External review. If the insurer still denies, you can file a written request within 4 months. Denials involving medical judgment qualify, and the insurer must accept the reviewer's decision (HealthCare.gov). In an urgent situation you can ask for external review at the same time as the internal appeal.

Keep every Explanation of Benefits, denial letter and note of each call (date, time, name, what was said). If you are in a flare during a delay, call the clinic the same day instead of waiting out the paperwork; our guide to when to go to the hospital for a UC flare covers the warning signs.

Can generics and biosimilars lower the cost?

Often, for the right drug. Generics apply to older small-molecule medicines such as some mesalamine forms. Biosimilars are highly similar versions of biologics such as infliximab. A review of 85 publications found switching from originator to biosimilar infliximab gave outcomes consistent with the originator, though data on repeated switching were limited (Lichtenstein 2024).

Two cautions apply. First, several of the review's authors work for a pharmaceutical company, and most included studies were observational, so this is supportive rather than final evidence. The European Crohn's and Colitis Organisation has also published a position statement on biosimilars in IBD (ECCO 2017). Second, whether a switch makes sense for you, and when, is for you and your IBD team to decide together, especially if you are in remission on your current drug. If you are curious, you can ask a simple question: "Is there a lower-cost version of this treatment, and would you be comfortable with it for me?"

If your biologic seems to be losing effect, that is a separate question with its own work-up, covered in what it means when a biologic stops working. And if you are starting a first infusion, what to expect at your first biologic infusion explains the day itself, including what to ask the infusion center about billing.

What about the UK, Canada and other countries?

Cost is very different outside the US. In England the NHS charges 9.90 pounds per prescribed item unless you are exempt, and a prepayment certificate can be cheaper if you need many items; Canada runs provincial plans with manufacturer compassionate programs on top; many other countries cover IBD drugs through public insurance. Always check your own country's current rules.

CountryWhat we could verifyWhat to ask
EnglandThe NHS charge is 9.90 pounds per item. A 3-month prepayment certificate costs 32.05 pounds, and a 12-month certificate costs 114.50 pounds and saves money if you need more than 11 items a year (NHS charges, NHS PPC).Whether you qualify for a different exemption. Rules differ between UK nations, so check yours.
CanadaProvincial plans differ. Alberta's, for example, lists a 30% co-payment up to a maximum per prescription and special authorization for high-cost drugs such as biologics (Crohn's and Colitis Canada). Manufacturers may offer compassionate discounts.Which provincial program you qualify for, and whether the drug's patient support program can help while approval is pending.
Australia and elsewherePosters in r/UlcerativeColitis describe public systems with low cost. We could not verify current rules from primary sources for this article.Check your national health service's site and your clinic's pharmacist.

If you are comparing countries because you are considering a move, ask your IBD team what the process would look like for your specific drug, and check how long coverage takes to start after you arrive.

Is it safe to skip doses, stretch pills or take someone else's mesalamine?

No. Skipping doses raises relapse risk, and medicine prescribed for someone else may be a different form, strength or product. In one prospective study of 99 people with quiescent ulcerative colitis on maintenance mesalamine, those who refilled less than 80% of prescribed medication had a hazard ratio of 5.5 for clinical recurrence (Kane 2003).

Put that in proportion. The study was small and observational, and nonadherence there was measured by refills for any reason, not only cost. But the direction is consistent with the wider adherence literature, which finds that adherence to aminosalicylates is often poor outside clinical trials and that this is linked to relapse and higher overall costs of care (Kane 2006). Any sign of financial toxicity, including cost-related skipping, was also associated with higher emergency department use among adults with IBD (Nguyen 2021).

What this means in practice:

  • Do not ration. If you are tempted to skip or stretch a dose, call your prescriber or pharmacist first. They may be able to change the pharmacy, the supply length or the form, or start an exception request.
  • Do not split or crush a product unless its label and your pharmacist say it is fine. Some mesalamine tablets are labeled to be swallowed whole (DailyMed Lialda label).
  • Do not take or give leftover pills. Another person's supply may not be the same form or product you were prescribed, and it bypasses the monitoring your own prescription involves, such as periodic kidney checks listed on the label. Many pharmacies and clinics can direct unused medicine to safe disposal.
  • Tell your team about cost early. They cannot adjust a plan around a cost problem they do not know about.

Which questions should I ask my clinic, pharmacist and insurer?

Ask each person for something they can actually do: the clinic for a letter or exception, the pharmacist for price comparison and form choices, the insurer for the exact rule behind the cost. A short checklist keeps one phone call from turning into five.

Ask your gastroenterology clinic

  • Can someone on the team check whether my drug needs a prior authorization or step therapy, and file it?
  • Is there a lower-cost option that you would be comfortable with for me, and if not, can you document why in a letter?
  • Do you have a social worker, nurse or pharmacist who handles assistance forms?
  • If my plan denies this, who will file the appeal, and how long should I wait before calling?
  • Our guide to questions to ask a gastroenterologist about colitis and the GI appointment preparation guide can help you fit these into the visit.

Ask your pharmacist

  • Which versions of this prescription are covered and cheapest on my plan?
  • What is the cash price for the same product and quantity?
  • Can I get 90 days, or mail order?
  • Does anything about my prescription mean it should not be split, crushed or stored in a particular way?

Ask your insurer or benefits office

  • Is this drug on my formulary, and at what tier?
  • Does it need prior authorization, step therapy or have a quantity limit?
  • Does manufacturer assistance count toward my deductible and out-of-pocket maximum, or are there accumulator or maximizer rules?
  • What is my deductible and out-of-pocket maximum, and how much have I met?
  • How do I file an exception request and an appeal, and what are the deadlines?

Can tracking help when I am arguing for coverage?

It can support the conversation, but it does not replace a doctor's letter. Insurers and prescribers think in terms of documented disease activity, prior treatments tried and why they failed. A dated record of symptoms, missed doses and flares gives your doctor material to work with when requesting an exception or appeal.

If you already log your symptoms, use it: bring your bowel pattern, flare dates and any medication changes. Our guide to symptom trackers for your doctor explains what a useful record looks like, and how to know if your ulcerative colitis is flaring covers what to note. Clairop, a free-to-download iPhone tracker, builds a one-page report for appointments from what you log; see how it works and our best apps for ulcerative colitis list if you are choosing one. It will not tell you what is covered or what to take.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

When should I see a doctor promptly?

Do not wait on a billing problem if your symptoms are changing. Contact your IBD team promptly, or seek urgent care, if you have more blood in your stool, rising stool frequency, fever, severe abdominal pain, a racing heart, dizziness, unexplained weight loss, or you cannot keep fluids down. These can signal a flare that needs treatment, not a paperwork delay.

If you have already missed doses because of cost, say so plainly. If the medicine is Rinvoq, our guide to what happens if you stop Rinvoq explains what the trial data show about gaps and what to write down. Clinics hear this often, and the answer is not shame but a plan: a bridge supply, an expedited authorization, an exception request or a program application. Our guide to how long a UC flare lasts and when to go to the hospital for a UC flare can help you judge how urgent things are, though it cannot replace a call to your team.

What myths about paying for ulcerative colitis medication should I ignore?

Several common beliefs are wrong or only partly right. Checking them can save money and prevent risky shortcuts. None of this replaces advice from your own prescriber, pharmacist or plan, because the right answer depends on your coverage and your drug.

  • "If I have insurance, I am protected." Not fully. In national survey data, financial hardship and cost-related nonadherence appeared even among privately insured and middle- or high-income adults with IBD (Nguyen 2021).
  • "A discount card is always cheaper than insurance." Not always. A card price may not count toward your deductible, so your year-end total can be higher.
  • "Copay cards work for everyone." No. They are for commercially insured patients, and accumulator or maximizer rules can blunt them.
  • "A denial means I cannot have the drug." No. Exceptions, appeals and external review exist, and the prescriber's letter matters most.
  • "Generic means weaker." The FDA states approved generics match the brand in dosage, safety, effectiveness, strength, stability and quality (FDA). Whether a particular form has a generic is a separate question.
  • "I can stretch my pills if I feel fine." Feeling well may be the medicine working. People in remission who refilled less than 80% of their mesalamine relapsed far more often in one study (Kane 2003).
  • "Taking a friend's leftover pills is harmless." It is not. The form, strength and monitoring can differ from your own prescription.

A one-page plan you can follow this week

If the cost feels overwhelming, do these in order. Each step takes under an hour, and each can lower your bill or open a program without touching your medicine.

  1. Write down every UC drug you take, its exact form and how it is billed (pharmacy or clinic).
  2. Call your plan for the formulary tier, any prior authorization and your deductible and out-of-pocket status.
  3. Ask your pharmacist for a plan price, a cash price and a 90-day option for each prescription.
  4. Ask your clinic whether there is a manufacturer program for any brand-name drug and who can help enroll you.
  5. If you have Medicare, check Extra Help and your plan's payment options; if you have no coverage, ask the clinic social worker about assistance programs and hospital financial aid.
  6. If anything is denied, ask the prescriber's office to start the exception or appeal, and keep a log of dates.
  7. Tell your IBD team about any dose you have already skipped or stretched.

This article is general information, not medical or financial advice. It does not recommend starting, stopping, switching or changing any medicine; those decisions belong to you and your prescriber. Programs, prices and rules change, so confirm details with the plan, program or pharmacy before relying on them.

Frequently asked questions

How can I afford ulcerative colitis medication without insurance?
In the US, start with the drug maker's patient assistance program (separate from the copay card, which needs commercial insurance), then nonprofit funds, hospital financial assistance and a pharmacy that publishes cash prices. Ask your clinic's social worker or pharmacist to help with forms. Tell your IBD team about the cost so they can adjust the plan safely rather than you cutting doses.
How much does mesalamine cost?
There is no single price. It depends on the form (delayed-release tablet, extended-release capsule, suppository or enema), whether a generic exists for that form, your plan's formulary and deductible, and the pharmacy. Generic versions of several forms are listed on DailyMed. Compare your plan price with a cash or discount-card price, and remember that cash purchases may not count toward your deductible.
Why is mesalamine so expensive for some people?
Usually because of the plan, not the molecule. A brand-only formulation, a formulary change, an unmet deductible or a non-preferred tier can each raise your share even when a cheaper generic exists for another form. Your doctor can ask the plan for a tiering or formulary exception, and your pharmacist can tell you which versions are cheapest on your plan.
Can I use a copay card if I have Medicare or Medicaid?
Generally no. Manufacturer copay cards are written for commercially insured patients, and federal anti-kickback rules are the reason they are kept away from Medicare and Medicaid. Medicare has its own routes instead: Extra Help, state pharmaceutical assistance programs, the Medicare Prescription Payment Plan and some manufacturer patient assistance programs.
Can I get free prescriptions with ulcerative colitis?
It depends on the country. In England, the NHS charges per item (currently 9.90 pounds) unless you qualify for an exemption, and a prepayment certificate can cap the cost; rules differ between the UK nations. Canada runs provincial drug plans plus manufacturer compassionate programs. In the US there is no general exemption, but assistance programs exist.
What if my insurance denies my ulcerative colitis medication?
Ask your prescriber's office to find out whether it is a prior authorization, step therapy or exception issue. On plans covered by the federal appeal rules you can file an internal appeal within 180 days, then request an independent external review within 4 months, and an urgent situation can run both at once. Keep every letter and date.
Are generics or biosimilars as good as the brand?
The FDA says approved generics match the brand in dosage, safety, effectiveness, strength, stability and quality. For biosimilar infliximab, a systematic review of 85 publications found switching outcomes consistent with the originator, though data on repeated switches are limited. Whether a switch suits you is a decision for your IBD team.
Is it safe to split pills, skip doses or take someone else's mesalamine to save money?
No. Some mesalamine tablets are labeled to be swallowed whole, not split or crushed, and a stranger's pills may be a different form, strength or product. Skipping doses is risky too: in one study, people refilling less than 80% of their mesalamine had about five times the risk of relapse. Talk to your prescriber about cost instead.
Does the Medicare out-of-pocket cap help with ulcerative colitis drugs?
Yes, for covered Part D drugs. Medicare states that spending is capped at 2,100 dollars in 2026 and 2,400 dollars in 2027, after which covered Part D drugs cost nothing for the rest of the year. Infusions given in a clinic are often billed through the medical benefit instead, which can work differently, so ask your plan and clinic how each of your drugs is billed.
What is the best way to keep track of costs and coverage paperwork?
A simple folder or notes file works: denial letters, appeal dates, drug names, prescriber letters and who you spoke to. If you also log symptoms and missed doses in an app such as Clairop, your doctor's report can show how you have been doing, which can support a letter of medical necessity. Cost tracking itself is manual.

Sources

  1. Liu C, Krane MK, Saxena N, Lee SD, Scott JW. Financial hardship among adults in the United States with inflammatory bowel disease: a national analysis. J Gastrointest Surg. 2026;30(11):102600. doi:10.1016/j.gassur.2026.102600
  2. Nguyen NH, Khera R, Dulai PS, Boktor M, Singh S, Ohno-Machado L, et al. National estimates of financial hardship from medical bills and cost-related medication nonadherence in patients with inflammatory bowel diseases in the United States. Inflamm Bowel Dis. 2021;27(7):1068-78. doi:10.1093/ibd/izaa266
  3. Kahn-Boesel O, Cautha S, Ufere NN, Ananthakrishnan AN, Kochar B. A narrative review of financial burden, distress, and toxicity of inflammatory bowel diseases in the United States. Am J Gastroenterol. 2023;118(9):1545-53. doi:10.14309/ajg.0000000000002345
  4. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
  5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(5):577-85. doi:10.1111/j.1365-2036.2006.02809.x
  6. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-224. doi:10.14309/ajg.0000000000003463
  7. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for ulcerative colitis. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/treatment
  8. US National Library of Medicine. DailyMed: mesalamine drug labels (generic delayed-release tablets, extended-release capsules, suppositories and rectal suspension). https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=mesalamine
  9. US National Library of Medicine. DailyMed: LIALDA (mesalamine) delayed-release tablets prescribing information, set id 3098a080-be86-4265-9818-7fc4beab77b7. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3098a080-be86-4265-9818-7fc4beab77b7
  10. US Food and Drug Administration. Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
  11. US Department of Health and Human Services Office of Inspector General. Special advisory bulletin: pharmaceutical manufacturer copayment coupons. September 2014. https://oig.hhs.gov/documents/special-advisory-bulletins/878/SAB_Copayment_Coupons.pdf
  12. Choi D, Zuckerman AD, Gerzenshtein S, Katsivalis M, Nichols C, Saknini MC, et al. A primer on copay accumulators, copay maximizers, and alternative funding programs. J Manag Care Spec Pharm. 2024;30(8):883-96. doi:10.18553/jmcp.2024.30.8.883
  13. Medicare.gov. Costs in the Part D coverage stages and ways to lower drug costs. https://www.medicare.gov/health-drug-plans/part-d/basics/costs
  14. Medicare.gov. Help with drug costs (Extra Help). https://www.medicare.gov/basics/costs/help/drug-costs
  15. Centers for Medicare & Medicaid Services. Prescription drug appeals and grievances: exceptions. https://www.cms.gov/medicare/appeals-grievances/prescription-drug/exceptions
  16. HealthCare.gov. Internal appeals. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
  17. HealthCare.gov. External review. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
  18. Constant BD, de Zoeten EF, Stahl MG, Vajravelu RK, Lewis JD, Fennimore B, et al. Delays related to prior authorization in inflammatory bowel disease. Pediatrics. 2022;149(3):e2021052501. doi:10.1542/peds.2021-052501
  19. Bhat S, Zahorian T, Robert R, Farraye FA, Mitrev N, Bhatt M, et al. Advocating for patients with inflammatory bowel disease: how to navigate the prior authorization process. Inflamm Bowel Dis. 2019;25(10):1621-8. doi:10.1093/ibd/izz013
  20. Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease: an update. J Crohns Colitis. 2017;11(1):26-34. doi:10.1093/ecco-jcc/jjw198
  21. Lichtenstein GR, Soonasra A, Latymer M, Singh S, Feagan BG. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease. Expert Opin Biol Ther. 2024;24(7):691-708. doi:10.1080/14712598.2024.2378090
  22. Internal Revenue Service. Financial assistance policy and emergency medical care policy: Section 501(r)(4). https://www.irs.gov/charities-non-profits/financial-assistance-policy-and-emergency-medical-care-policy-section-501r4
  23. NHS. NHS prescription charges. https://www.nhs.uk/nhs-services/prescriptions-and-pharmacies/nhs-prescription-charges/
  24. NHS. Save money with a prescription prepayment certificate (PPC). https://www.nhs.uk/nhs-services/prescriptions-and-pharmacies/save-money-with-a-prescription-prepayment-certificate-ppc/
  25. Crohn's and Colitis Canada. IBD journey: provincial government drug coverage. https://crohnsandcolitis.ca/about-crohn-s-colitis/ibd-journey/Insurance-Government-Support/Provincial-Government
  26. Crohn's & Colitis Foundation. Patient financial assistance programs. https://www.crohnscolitisfoundation.org/managing-the-cost-of-ibd/patient-financial-assistance
  27. MyCrohnsAndColitisTeam. 5 ways to reduce the cost of Crohn's and colitis medication. 2026. https://www.mycrohnsandcolitisteam.com/resources/5-ways-to-reduce-the-cost-of-crohns-and-colitis-medication

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools